scholarly journals Improved body weight and performance status and reduced serum PGE2levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction

2015 ◽  
Vol 6 (1) ◽  
pp. 32-44 ◽  
Author(s):  
Joyce Faber ◽  
Madeleen J. Uitdehaag ◽  
Manon Spaander ◽  
Sabine van Steenbergen-Langeveld ◽  
Paul Vos ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Body Weight ◽  
Performance Status ◽  
Nutritional Intervention ◽  
Newly Diagnosed ◽  
Medical Food ◽  
And Performance

PP292 IN NEWLY DIAGNOSED ESOPHAGEAL CANCER PATIENTS SERUM PGE2 LEVELS ARE REDUCED AFTER NUTRITIONAL INTERVENTION WITH A MEDICAL FOOD

2010 ◽  
Vol 5 (2) ◽  
pp. 137
Author(s):  
J. Faber ◽  
V.M. Spaander ◽  
S.C. van Steenbergen ◽  
A.P. Vos ◽  
M. Berkhout ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Patients ◽  
Nutritional Intervention ◽  
Newly Diagnosed ◽  
Medical Food

scholarly journals Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Sung Min Kim ◽  
Moon Jin Kim ◽  
Hyun Ae Jung ◽  
Kihyun Kim ◽  
Seok Jin Kim ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Elderly Patients ◽  
Performance Status ◽  
Solid Cancer ◽  
Newly Diagnosed ◽  
History Of ◽  
Comorbidity Index ◽  
And Performance ◽  
The Impact

Multiple myeloma occurs primarily in elderly patients. Considering the high prevalence of comorbidities, comorbidity is an important issue for the management of myeloma. However, the impact of comorbidity on clinical outcomes has not been fully investigated. We retrospectively analyzed patients with newly diagnosed myeloma. Comorbidities were assessed based on the Charlson comorbidity index (CCI) and the Freiburg comorbidity index (FCI). The CCI is a summary measure of 19 comorbid conditions. FCI is determined by performance status, renal impairment, and lung disease. This study included 127 patients with a median age of 71 years. Approximately half of the patients had additional disorders at the time of diagnosis, and diabetes mellitus was the most frequent diagnosis (18.9%). The most significant factors for prognosis among patient-related conditions were a history of solid cancer and performance status (ECOG ≥ 2). The FCI score was divided into 3 groups (0, 1, and 2-3), and the CCI score was divided into 2 groups (2-3 and ≥4). FCI was a strong prognostic tool for OS (P>0.001) and predicted clinical outcome better than CCI (P=0.059). In conclusion, FCI was more useful than CCI in predicting overall survival in elderly patients with myeloma.

Selection bias, survival, and brachytherapy for glioma

1992 ◽  
Vol 76 (2) ◽  
pp. 179-183 ◽  
Author(s):  
Randall C. Florell ◽  
David R. Macdonald ◽  
William D. Irish ◽  
Mark Bernstein ◽  
Steven A. Leibel ◽  
...  
Keyword(s):  
Patient Selection ◽  
Survival Data ◽  
Randomized Trials ◽  
Performance Status ◽  
Population Based ◽  
Newly Diagnosed ◽  
Content Type ◽  
Promising Treatment ◽  
And Performance ◽  
The Impact

✓ Interstitial irradiation is a promising treatment for malignant glioma. Longer than expected survival periods following treatment of recurrent tumor have led to the use of brachytherapy as an adjuvant treatment. The impact of patient selection on survival data was studied among candidates for this therapy. Consecutive, conventionally treated adults with newly diagnosed supratentorial tumors were identified retrospectively at a center where experience with glioma is population-based. Based on imaging and performance status, two surgeons and a radiation oncologist designated each patient as either eligible or ineligible for adjuvant brachytherapy. The survival and prognostic factors in the eligible and ineligible groups were analyzed. Overall, the patients eligible for brachytherapy (32% of the series) lived significantly longer than the ineligible patients (16.57 vs. 9.30 months), were younger, and had larger resections and better function. For glioblastoma, 40% of patients were eligible, and lived much longer than those who were ineligible (13.90 vs. 5.80 months). It is concluded that better outcome following adjuvant brachytherapy for glioma is at least in part the result of patient selection. Randomized trials of comparably selected patients will be necessary to demonstrate conclusively that longer survival is also a result of treatment.

Stage distribution and performance status of newly diagnosed patients in a UK regional mesothelioma centre

Lung Cancer ◽  
2014 ◽  
Vol 85 (1) ◽  
pp. 99-100 ◽  
Author(s):  
Shahul Khan ◽  
Matthew Evison ◽  
Mohamed Alaloul ◽  
Jayne Holme ◽  
Richard Booton ◽  
...  
Keyword(s):  
Performance Status ◽  
Newly Diagnosed ◽  
Stage Distribution ◽  
And Performance

scholarly journals A standardized, integral nutritional intervention and physical activity program reduces body weight in women newly diagnosed with breast cancer

2021 ◽  
Author(s):  
Cristina Santurino ◽  
Marina Morato-Martínez ◽  
Bricia López-Plaza ◽  
Lucía Arcos-Castellanos ◽  
Marta Clavero-Fraile ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Body Weight ◽  
Nutritional Intervention ◽  
Physical Activity Program ◽  
Newly Diagnosed ◽  
Activity Program

Untreated Patients with Acute Myeloid Leukemia, Age 50–59 Years and Performance Status 2 Should Be as Eligible for Targeted Therapy as Older Patients.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2864-2864
Author(s):  
Apostolia M. Tsimberidou ◽  
Hagop M. Kantarjian ◽  
Stefan Faderl ◽  
Sherry Pierce ◽  
Emil J. Freireich ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Performance Status ◽  
Newly Diagnosed ◽  
Death Rates ◽  
Targeted Treatments ◽  
High Death ◽  
And Performance ◽  
Acute Myeloid

Abstract Background: The early mortality rates in older patients (generally defined as those > 60 years) following standard therapy for acute myeloid leukemia (AML), has spurred numerous trials of “targeted” treatments, typically limited to this age group. Here we examine whether younger patients with Zubrod performance status (PS) 2 might also be candidates for these therapies. Patients and Methods: We reviewed the records of 1841 patients 40 years or older with newly diagnosed AML (no acute promyelocytic leukemia) who received cytarabine-containing therapy at M. D. Anderson from 1980 to 2007. We chose patients with the following pretreatment characteristics because they are conventional criteria for entry onto trials of new therapies: PS 0–2, bilirubin < 2 mg/dL, and creatinine < 2 mg/dL. We calculated death rates by age and PS at 28 and 42 days after initiation of induction therapy. Results: Induction death rates in patients with AML by age and performance status The 28-day death rates in patients age 50–59 years with PS 2 were similar to those in patients ≥ 60 years with PS 0–1, and the 42-day death rates in the patients age 50–59 years with PS 2 were similar to those in patients age 60–79 with PS 0–1. Conclusion: Because of the high death rates following AML therapy in patients age 50–59 with PS 2, these patients should be eligible for targeted treatments now limited to older patients. Age, yrs Performance Status No. of Patients Dead by day 28, % Dead by day 42 % 40–49 0–1 288 7 9 40–49 2 38 5 5 50–59 0–1 405 4 6 50–59 2 85 14 15 60–69 0–1 423 8 11 60–69 2 111 17 17 70–79 0–1 301 12 16 70–79 2 124 23 33 ≥80 0–1 45 13 20 ≥ 80 2 21 38 43

Risks of severe adverse events of docetaxel, cisplatin, and 5-fluorouracil (DCF) combination chemotherapy of esophageal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 43-43 ◽  
Author(s):  
Sayako Yuda ◽  
Ken Kato ◽  
Yusuke Sasaki ◽  
Naoki Takahashi ◽  
Hirokazu Shoji ◽  
...  
Keyword(s):  
Risk Factors ◽  
Esophageal Cancer ◽  
Adverse Events ◽  
Clinical Stage ◽  
Performance Status ◽  
Clinical Situation ◽  
Cancer Center ◽  
Increased Risk ◽  
Severe Adverse Events ◽  
And Performance

43 Background: Although adding docetaxel to cisplatin plus 5-fluorouracil (i.e. the DCF regimen) for esophageal cancer treatment may improve outcomes, this regimen has increased toxicity. However, the risk factors for severe non-hematological toxicities remain unknown. Methods: We analyzed data on esophageal cancer patients given at least one cycle of DCF between July 2009 and April 2014 at the National Cancer Center Hospital, Japan. DCF consisted of docetaxel 70 mg/m2/day (day 1), cisplatin 70 mg/m2/day (day 1), and continuous infusion of 5-fluorouracil 750 mg/m2/day (days 1–5), repeated every 3 weeks. Data on adverse events developing within three cycles were collected from medical records. Risk factors for severe adverse events were analyzed. Results: One hundred patients were enrolled, with a median age of 63 (range, 37 to 76); 81 male and 19 female; 96 squamous cell carcinomas and 4 adenocarcinomas; clinical situation neoadjuvant/induction/palliative: 69/23/8/1; clinical stage I/II/III/IV: 1/12/64/23; and performance status (PS) 0/1/2: 44/55/1. Forty patients (40%) developed grade 3 or more non-hematological adverse events, including anorexia (12%), mucositis (6%), and esophagitis (2%); 45 developed grade 4 hematological adverse events. Seventeen experienced febrile neutropenia (FN). There was one case of treatment-related death from serious infection. In multivariate analysis, age≥63 was at significantly increased risk of FN (P=0.013). Conclusions: DCF chemotherapy was safe in most patients and its toxicity was controllable. However, elderly patients may suffer from intense toxicity during DCF therapy.

Sign in / Sign up

Export Citation Format

Share Document